SCHEMBL3607653

SCHEMBL3607653

CCN(CC)CCOc1ccc(Nc2ncc(-c3ccccc3Cl)s2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RIPK2 O43353 5/20 0.54
ACVR1 Q04771 5/20 0.54
NOD2 Q9HC29 5/20 0.54
WEE1 P30291 4/20 0.52
LIMK1 P53667 3/20 0.50
LIMK2 P53671 1/20 0.49
HRH3 Q9Y5N1 1/20 0.48
FGFR1 P11362 4/20 0.47
SRC P12931 4/20 0.47
KDR P35968 3/20 0.47
ABL1 P00519 2/20 0.47
EGFR P00533 2/20 0.47
PDGFRB P09619 2/20 0.47
LCK P06239 2/20 0.47
CHEK1 O14757 1/20 0.47
JAK2 O60674 1/20 0.47
PRKD3 O94806 1/20 0.47
MAP4K4 O95819 1/20 0.47
PAK4 O96013 1/20 0.47
NTRK1 P04629 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13165677 0.89 LIMK1 (0.52) RIPK2ACVR1NOD2WEE1LIMK1
SCHEMBL3611617 0.77 CDK4 (0.45) RIPK2ACVR1NOD2HRH3SRC
SCHEMBL3599596 0.77 KDR (0.46) RIPK2ACVR1NOD2WEE1HRH3
SCHEMBL3600168 0.75 LIMK1 (0.78) LIMK1LIMK2KDRMAPK14
SCHEMBL3597672 0.74 KDR (0.45) RIPK2ACVR1NOD2WEE1HRH3
SCHEMBL29498169 0.74 RIPK2 (0.65) RIPK2ACVR1NOD2WEE1FGFR1
SCHEMBL11816680 0.73 NPC1 (0.62)
SCHEMBL11878533 0.73 CYP2D6 (0.65) RIPK2ACVR1NOD2HRH3SRC
SCHEMBL3313176 0.71 RIPK2 (0.60) RIPK2ACVR1NOD2WEE1FGFR1
SCHEMBL29498246 0.70 RIPK2 (1.00) RIPK2ACVR1NOD2WEE1FGFR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1687285-B1 THIAZOLE AND PYRAZOLE DERIVATIVES AS FLT-3 KINASE INHIBITORS NOVARTIS AG (CH) 2014-03-05 EP claimed
US-7795288-B2 Thiazole and pyrazole derivatives as Flt-3 kinase inhibitors NOVARTIS AG (CH) 2010-09-14 US claimed
US-20070167449-A1 Thiazole and pyrazole derivatives as flt-3 kinase inhibitors NOVARTIS PHARMA AG (CH) 2007-07-19 US claimed
EP-1687285-B1 THIAZOLE AND PYRAZOLE DERIVATIVES AS FLT-3 KINASE INHIBITORS NOVARTIS AG (CH) 2014-03-05 EP disclosed
US-7795288-B2 Thiazole and pyrazole derivatives as Flt-3 kinase inhibitors NOVARTIS AG (CH) 2010-09-14 US disclosed
US-20070167449-A1 Thiazole and pyrazole derivatives as flt-3 kinase inhibitors NOVARTIS PHARMA AG (CH) 2007-07-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070167449-A1 Thiazole and pyrazole derivatives as flt-3 kinase inhibitors FLT3, FLT1, FLT4 RIPK2 642/4885ACVR1 297/4885NOD2 410/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.